Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11638233 | 0.86 | PTK2 (0.59) | HPGDNPC1RAB9ATP53MAPT | |
| SCHEMBL4066836 | 0.84 | KMT2A (0.67) | NPC1RAB9AMAPTL3MBTL1PTK2 | |
| SCHEMBL9396580 | 0.84 | MEN1 (0.48) | HPGDNPC1RAB9ATP53MAPT | |
| SCHEMBL9398335 | 0.82 | PKM (0.47) | HPGDNPC1RAB9ATP53MAPT | |
| SCHEMBL31469754 | 0.81 | MEN1 (0.50) | HPGDNPC1RAB9ATP53MAPT | |
| SCHEMBL3798512 | 0.81 | RPS6KB1 (0.52) | HPGDNPC1RAB9ATP53MAPT | |
| SCHEMBL4063794 | 0.79 | TLR2 (0.54) | HPGDNPC1RAB9ATP53MAPT | |
| SCHEMBL7842718 | 0.79 | TSHR (0.46) | HPGDNPC1RAB9ATP53MAPT | |
| SCHEMBL6643211 | 0.79 | ALDH1A1 (0.53) | HPGDNPC1RAB9ATP53MAPT | |
| SCHEMBL6636910 | 0.79 | TSHR (0.46) | HPGDNPC1RAB9ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-2875018-B1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-3208270-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9475824-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475824-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-9062026-B2 | Fused pyrimidines and substituted quinazolines as inhibitors of p97 | CLEAVE BIOSCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062026-B2 | Fused pyrimidines and substituted quinazolines as inhibitors of p97 | CLEAVE BIOSCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | CLEAVE BIOSCIENCES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | CLEAVE BIOSCIENCES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | PSMG3, PSME1, PSMB1 | HPGD 2954/4885NPC1 1419/4885RAB9A 2030/4885 |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | PSMG3, PSMD1, PSMD3 | HPGD 3030/4885NPC1 1797/4885RAB9A 1209/4885 |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | PSMG3, PSME1, PSMB1 | HPGD 2954/4885NPC1 1419/4885RAB9A 2030/4885 |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | PSMG3, PSME1, PSMB1 | HPGD 2954/4885NPC1 1419/4885RAB9A 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.